The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, cross-over study
Abstract
Thirty patients with definite or probable chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) of chronic progressive (16 patients) or relapsing (14 patients) course were randomly assigned to receive intravenous immunoglobulin (IvIg) 0.4 g per kg body weight or a placebo treatment on 5 consecutive days in a double-blind, cross-over trial. Neurological function was monitored by serial quantitative assessments [neurological disability score (NDS); clinical grade (CG) and grip strength (GS) measurements] and by electrophysiological studies before and after each treatment period. Twenty-five patients completed both treatment periods. A comparison of the observed changes in clinical outcome measures revealed statistically significant differences in favour of IvIg, with (mean +/- SD) improvements in NDS by 24.4 +/- 5.4 points (P < 0.002) in CG by 1 +/- 0.3 points (P < 0.001) in GS by +6.3 +/- 1.7 kg (P < 0.005), whereas scores were unchanged or worse with placebo. A secondary two-groups analysis of the first trial period included all 30 patients; 16 patients had been randomly assigned to IvIg and 14 to placebo treatments. Again significant differences in favour of IvIg were observed in all the clinical end-points: improvement in NDS was 35.6 +/- 25 points (P < 0.0001), in CG it was 1.3 +/- 1.9 points (P < 0.002) and in GS +9.8 +/- 7.7 kg (P < 0.001), whereas all scores worsened with placebo. Of the 30 patients, 19 (63%) improved with IvIg treatments; nine out of 16 patients (56%) with chronic progressive CIDP, and 10 out of 14 patients (71%) with relapsing CIDP (differences were not statistically significant). A placebo response was seen in five patients. Comparison of paired electrophysiological measurements before and 4 weeks after IvIg treatments revealed statistically significant improvements in the summed motor conduction velocities (sigma MCV; P < -0.0001) and in the summed compound muscle action potentials (CMAP) evoked with proximal stimulation (sigma proximal CMAP, P < 0.03) of median, ulnar, peroneal and tibial nerves. Eight of nine IvIg responders with chronic progressive CIDP improved gradually to normal function with a single 5 day course of IvIg; in five of these, small doses of prednisone were prescribed during follow-up. In 10 IvIg responders with relapsing CIDP, improvements lasted a median 6 weeks (range 3-22 weeks) and was reproducible with open label treatments. All 10 patients have been maintained and stabilized with IvIg pulse therapy of 1 g per kg body weight or less, given as a single infusion prior to the expected relapse. A beneficial response to IvIg was found to be most likely in patients with acute relapse or with disease of one year or less. Patients with predominantly sensory signs did not improve.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reliability and validity of grip and pinch strength evaluations
Mathiowetz, V., Weber, K., Volland, G., & Kashman, N. (1984) · The Journal of Hand Surgery · doi:10.1016/s0363-5023(84)80146-x · Cited by 1,857
Chronic Inflammatory Polyradiculoneuropathy
Millichap, J. G. (1997) · Pediatric Neurology Briefs · doi:10.15844/pedneurbriefs-11-12-6 · Cited by 822
Manipulating the Immune System with Immune Globulin
Oates, J. A., Wood, A. J. J., & Dwyer, J. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260206 · Cited by 648
Barohn, R. J. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440064022 · Cited by 567
Plasma Exchange in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Dyck, P. J., Daube, J., O'Brien, P., Pineda, A., Low, P. A., Windebank, A. J., & Swanson, C. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602203140801 · Cited by 489
Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment
Dyck, P. J., O'Brien, P. C., Oviatt, K. F., Dinapoli, R. P., Daube, J. R., Bartleson, J. D., Mokri, B., Swift, T., Low, P. A., & Windebank, A. J. (1982) · Annals of Neurology · doi:10.1002/ana.410110205 · Cited by 483
Dyck, P. J., Litchy, W. J., Kratz, K. M., Suarez, G. A., Low, P. A., Pineda, A. A., Windebank, A. J., Karnes, J. L., & O'Brien, P. C. (1994) · Annals of Neurology · doi:10.1002/ana.410360607 · Cited by 471
MCOMBE, P. A., POLLARD, J. D., & MCLEOD, J. G. (1987) · Brain · doi:10.1093/brain/110.6.1617 · Cited by 458
Hahn, A. F., Bolton, C. F., Pillay, N., Chalk, C., Benstead, T. J., Bril, V., Shumak, K. H., Vandervoort, M. K., & Feasby, T. E. (1996) · Brain · doi:10.1093/brain/119.4.1055 · Cited by 409
Self-citationTreatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcγ-Receptor Antibody
Clarkson, S. B., Bussel, J. B., Kimberly, R. P., Valinsky, J. E., Nachman, R. L., & Unkeless, J. C. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605083141907 · Cited by 365
Effect of high-dose intravenous immunoglobulin therapy on blood rheology
Reinhart, W. H., & Berchtold, P. E. (1992) · The Lancet · doi:10.1016/0140-6736(92)90806-e · Cited by 208
Rossi, F., Dietrich, G., & Kazatchkine, M. D. (1989) · Immunological Reviews · doi:10.1111/j.1600-065x.1989.tb00031.x · Cited by 182
Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy
Vermeulen, M., van der Meché, F. G. A., Speelman, J. D., Weber, A., & Busch, H. F. M. (1985) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(85)90173-x · Cited by 178
Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease
Thornton, C. A., & Griggs, R. C. (1994) · Annals of Neurology · doi:10.1002/ana.410350304 · Cited by 115
Subacute Idiopathic Demyelinating Polyradiculoneuropathy
Hughes, R. A., Sanders, E., Hall, S. M., Atkinson, P. F., Colchester, A. C. F., & Payan, P. C. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530300044009 · Cited by 112
van Doorn, P. A., Rossi, F., Brand, A., van Lint, M., Vermeulen, M., & Kazatchkine, M. D. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90147-f · Cited by 93
High-dose intravenous IgG treatment and renal function
Schifferli, J. A., Leski, M., Favre, H., Imbach, P. A., Nydegger, U., & Davies, K. A. (1991) · The Lancet · doi:10.1016/0140-6736(91)93395-p · Cited by 92
Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin
Cornblath, D. R., Chaudhry, V., & Griffin, J. W. (1991) · Annals of Neurology · doi:10.1002/ana.410300119 · Cited by 92
High‐dose intravenous human immuno‐globulin in chronic inflammatory demyelinating polyneuropathy
Faed, J. M., Day, B., Pollock, M., Taylor, P. K., Nukada, H., & Hammond-Tooke, G. D. (1989) · Neurology · doi:10.1212/wnl.39.3.422 · Cited by 90
Complications of Plasma Exchange in Neurological Patients
Rodnitzky, R. L., & Goeken, J. A. (1982) · Archives of Neurology · doi:10.1001/archneur.1982.00510180028007 · Cited by 81
Anderson, C. L. (1989) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(89)90071-8 · Cited by 53
Vedanarayanan, V., Kandt, R. S., Lewis, D. V., & DeLong, G. R. (1991) · Neurology · doi:10.1212/wnl.41.6.828 · Cited by 45
van Doorn, P. A., Brand, A., & Vermeulen, M. (1988) · Neurology · doi:10.1212/wnl.38.10.1592 · Cited by 44
Hahn, A. F., Chang, Y. T., & Webster, H. D. (1987) · The Journal of Comparative Neurology · doi:10.1002/cne.902600403 · Cited by 36
Self-citationDyck, P. J. B. (1990) · Neurology · doi:10.1212/wnl.40.2.327 · Cited by 31
High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy
Dossi, B. C., & Tezzon, F. (1987) · Neurological Sciences · doi:10.1007/bf02335733 · Cited by 27
Normal Polyspecific Immunoglobulin G (IVIg) in the Treatment of Autoimmune Diseases
Hurez, V. J., Kaveri, S. V., & Kazatchkine, M. D. (1993) · Journal of Autoimmunity · doi:10.1006/jaut.1993.1056 · Cited by 22
Guillain-Barré syndrome and CIDP
Hartung, H. ‐., Reiners, K., Toyka, K. V., et al. (1994) · Springer eBooks · doi:10.1007/978-94-011-1422-6_3 · Cited by 16
Cited by
Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin
Kazatchkine, M. D., & Kaveri, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejmra993360 · Cited by 1,209
Hughes, R. A., Donofrio, P., Bril, V., Dalakas, M. C., Deng, C., Hanna, K., Hartung, H.-P., Latov, N., Merkies, I. S., & van Doorn, P. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70329-0 · Cited by 674
Update on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
ORANGE, J., HOSSNY, E., WEILER, C., BALLOW, M., BERGER, M., BONILLA, F., BUCKLEY, R., CHINEN, J., ELGAMAL, Y., & MAZER, B. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.015 · Cited by 653
Hughes, R., Bensa, S., Willison, H., Van Den Bergh, P., Comi, G., Illa, I., Nobile‐Orazio, E., Van Doorn, P., Dalakas, M., Bojar, M., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1088 · Cited by 628
Metadata
- Authors
- Hahn, A. F., Bolton, C. F., Zochodne, D., & Feasby, T. E.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-08-01
- Volume
- 119
- Issue
- 4
- Pages
- 1067-1077
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2965965202
- Cited by
- 439
- References
- 28
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.